

FITC-Labeled Human EGFRVIII Protein

Cat. No. EG8-HM154F

Description

Source	Recombinant FITC-Labeled Human EGFRVIII Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. It contains Leu25-Ser378.
Accession	NP_001333870.1
Molecular Weight	The protein has a predicted MW of 41.6 kDa. Due to glycosylation, the protein migrates to 68-80 kDa based on Tris-Bis PAGE result.
Wavelength	Excitation Wavelength: 490 nm Emission Wavelength: 520 nm
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE

Formulation and Storage


Formulation	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Storage	Valid for 12 months from date of receipt when stored at -80°C . Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRVIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.


Assay Data

Tris-Bis PAGE



FITC-Labeled Human EGFRVIII on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

FACS Data



FACS Analysis of Anti-EGFRVIII CAR Expression. 293T cells were transfected with anti-EGFRVIII-scFv and His tag. Cells were incubated with 5 $\mu\text{g}/\text{ml}$ FITC-Labeled Human EGFRVIII, His Tag and FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.